Odd Lots cover image

Here Comes the Booming Chinese Biotech Sector

Odd Lots

00:00

Contrasting Drug Development: China vs. U.S. Regulatory Dynamics

This chapter explores the differences in drug development regulations between China and the United States, focusing on the advantages of China's quicker patient access through phase zero studies. It also examines the challenges and financial aspects of conducting clinical trials in the U.S., highlighting the disparities in healthcare systems and incentives for medical professionals.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app